Neutrophils News and Research

RSS

Asbestos awareness important to prevent related cancer: Experts

Experts from Perth speculate Western Australia is yet to see the peak of asbestos-induced cancer, with renovators still failing to take proper precautions. According to director of the National Centre for Asbestos Related Diseases, Bruce Robinson, the next and third wave of mesothelioma patients would come out of those putting themselves and others at risk while taking on DIY home renovation projects.

22 Nov 2010

Researchers reveal mechanism of early-stage anthrax infection

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have determined a key mechanism by which Bacillus anthracis bacteria initiate anthrax infection despite being greatly outnumbered by immune system scavenger cells. The finding, made by studying genetically modified mice, adds new detail to the picture of early-stage anthrax infection and supports efforts to develop vaccines and drugs that would block this part of the cycle.

18 Nov 2010

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.

9 Nov 2010

La Jolla Institute scientist wins Malpighi Medal for pioneering work in heart disease

Klaus Ley, M.D, a scientist at the La Jolla Institute for Allergy & Immunology, was recently awarded the prestigious Malpighi Medal at the World Congress for Microcirculation in Paris, France. A lifetime achievement award presented by the European Society for Microcirculation, Dr. Ley received the honor in recognition of his pioneering endeavors in vascular immunology, a scientific discipline that he helped to pioneer, which looks at novel immune-based approaches to combating heart disease. He is only the 17th recipient of the biennial award worldwide.

26 Oct 2010

Study reveals two enzymes help immune cells deploy pathogen-killing traps

A new study reveals that two enzymes help immune cells deploy pathogen-killing traps by unraveling and using the chromatin (DNA and its associated proteins) contained in the cells' nuclei to form defensive webs. The study appears online on October 25 in The Journal of Cell Biology.

26 Oct 2010

BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting

BioCryst Pharmaceuticals, Inc. announced the presentation of data related to intravenous (i.v.) peramivir for the treatment of influenza at the 48th Annual Infectious Diseases Society of America (IDSA) meeting being held in Vancouver, Canada.

21 Oct 2010

New imaging technique to study response of white blood cells to inflammation

Researchers at the University of Calgary Faculty of Medicine are using an innovative new imaging technique to study how white blood cells (called neutrophils) respond to inflammation, and have revealed new targets to inhibit the response.

18 Oct 2010

Moores Cancer Center files IND application for topical NexACT-based formulation

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).

15 Oct 2010

Pfizer announces tasocitinib Phase 2 data for plaque psoriasis

Pfizer Inc. today announced that data from a Phase 2 efficacy and safety study of tasocitinib the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.

8 Oct 2010

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

The way melanoma cells use the immune system to spread and develop into lung tumors may lead to a therapy to decrease development of these tumors, according to Penn State researchers.

8 Oct 2010

Research finds immune system mechanism to minimize collateral damage

A study published today in the journal Science shows how our bodies try to minimise potential 'collateral damage' caused by our immune system when fighting infection. The research may also provide new clues to why cigarette smoke is a significant risk factor for developing diseases of the lung such as chronic bronchitis and emphysema.

3 Sep 2010

Cigarette smoke inhibits LTA4H enzyme, regulates body's response to inflammation: Study

Cigarette smoke shuts off a key enzyme in airways that regulates the body's response to inflammation, according to findings from the University of Alabama at Birmingham published online today at Science Express.

3 Sep 2010

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).

2 Sep 2010

MGH scientists develop new microfluidic tool for accurate isolation of neutrophils

A team led by Massachusetts General Hospital (MGH) scientists has developed a new microfluidic tool for quickly and accurately isolating neutrophils - the most abundant type of white blood cell - from small blood samples, an accomplishment that could provide information essential to better understanding the immune system's response to traumatic injury. The system, described in a Nature Medicine paper that received advance online release, also can be adapted to isolate almost any type of cell.

31 Aug 2010

Research marks new direction to treat Pneumocystis, inflammatory diseases

A drug to treat inflammation plays a surprising role reducing the level of infection caused by an opportunistic bug that is deadly for AIDS and cancer patients and others with weakened immune systems.

20 Aug 2010

Scientists analyze new technique to quickly identify particular asthma subtypes

For many people afflicted by asthma, treatment can be a frustrating and time-consuming experience. After their initial diagnosis, asthmatics find themselves caught in a trial and error process that can last for months, as doctors gradually escalate their medications to treat their condition effectively with minimal side effects. And until the right medicine and dosage are found, patients continue to suffer attacks that strike without warning and can leave them struggling for breath for hours or even days.

5 Aug 2010

Blood coagulation, antimicrobial defence processes are functionally coupled: Research

The adaptive immune system can recognize and respond specifically to particular infectious agents. But the first line of defence against pathogens is the so-called innate immune system. This system reacts to invaders by initiating unspecific inflammatory responses which attract various types of specialized cells such as neutrophils to the site of the incursion.

4 Aug 2010

Lundbeck voluntarily recalls two lots of NeoProfen Injection

Lundbeck Inc. has voluntarily recalled two lots of NeoProfen® (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement. These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage. This voluntary recall is the result of the company's inspections of the two product lots of NeoProfen.

31 Jul 2010

Abbot's innovative solutions to be highlighted at AACC

A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.

27 Jul 2010

UMDNJ identifies direct link between phthalates in plastics and inflammation in newborns

Researchers at the University of Medicine and Dentistry of New Jersey (UMDNJ) have identified a direct link between phthalates, the substances that make plastics more pliable and durable, and inflammation in newborns - and are encouraging more limited use of the plasticizers. Their paper, "Inflammatory Effects of Phthalates in Neonatal Neutrophils," appears in the August 2010 edition of the journal Pediatric Research.

21 Jul 2010